Bioventus Receives Consensus Buy Rating from Analysts

Analysts see potential upside for the medical device company's stock.

Mar. 13, 2026 at 4:50am

Got story updates? Submit your updates here. ›

Shares of Bioventus Inc. (NASDAQ:BVS) have received an average recommendation of "Buy" from the five research firms currently covering the company, according to Marketbeat. One analyst has rated the stock as a "hold", three have assigned a "buy" rating, and one has given it a "strong buy" rating. The average 12-month price target among analysts is $14.25.

Why it matters

Bioventus is a global medical device company focused on orthobiologic solutions, including products that accelerate bone healing and manage osteoarthritis pain. Positive analyst sentiment on the stock suggests Wall Street sees potential upside for the company as it continues to commercialize its portfolio of non-surgical therapies.

The details

Several research firms have recently weighed in on Bioventus. Craig Hallum boosted their price target on the stock from $15 to $16 and maintained a "buy" rating. Cantor Fitzgerald raised its rating on Bioventus to "strong buy", while Barrington Research increased its price target to $14 and kept an "outperform" rating. Weiss Ratings, meanwhile, reiterated a "hold (c-)" rating on the shares.

  • Bioventus released its Q4 2025 financial results on March 6, 2026.

The players

Bioventus Inc.

A global medical device company specializing in orthobiologic solutions for musculoskeletal conditions.

Craig Hallum

An investment research firm that covers Bioventus.

Cantor Fitzgerald

An investment bank that covers Bioventus.

Barrington Research

An investment research firm that covers Bioventus.

Weiss Ratings

A financial research firm that covers Bioventus.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The positive analyst sentiment on Bioventus suggests Wall Street sees potential upside for the company as it continues to commercialize its portfolio of orthobiologic solutions, which could bode well for the stock's future performance.